Navelbine [vinorelbine] Taxol [paclitaxel] Herceptin [trastuzumab] and Neuopogen [filgrastim] in stage IV breast cancer: A phase I-II trial

Trial Profile

Navelbine [vinorelbine] Taxol [paclitaxel] Herceptin [trastuzumab] and Neuopogen [filgrastim] in stage IV breast cancer: A phase I-II trial

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Filgrastim; Paclitaxel; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 May 2017 Status changed from completed to discontinued.
    • 01 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2008 Planned end date changed from 1 Mar 2008 to 1 Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top